Bridgepoint-backed Swedish renal clinic operator Diaverum has scrapped its plans for an IPO, two weeks after it announced its intention to float on Nasdaq Stockholm.
Bridgepoint-backed Swedish renal clinic operator Diaverum has scrapped its plans for an IPO, two weeks after it announced its intention to float on Nasdaq Stockholm.